• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Addition of histone deacetylase inhibitors in combination therapy.

作者信息

Carraway Hetty E, Gore Steven D

出版信息

J Clin Oncol. 2007 May 20;25(15):1955-6. doi: 10.1200/JCO.2006.09.8293.

DOI:10.1200/JCO.2006.09.8293
PMID:17513801
Abstract
摘要

相似文献

1
Addition of histone deacetylase inhibitors in combination therapy.
J Clin Oncol. 2007 May 20;25(15):1955-6. doi: 10.1200/JCO.2006.09.8293.
2
Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study.丙戊酸抑制组蛋白去乙酰化酶后联合拓扑异构酶II抑制剂表柔比星治疗晚期实体瘤的I期试验：一项临床与转化研究
J Clin Oncol. 2007 May 20;25(15):1979-85. doi: 10.1200/JCO.2006.08.6165.
3
Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC.丙戊酸作为组蛋白去乙酰化酶抑制剂对肿瘤及替代组织的临床和生物学效应：丙戊酸与表柔比星/FEC的I/II期试验
Clin Cancer Res. 2009 Apr 1;15(7):2488-96. doi: 10.1158/1078-0432.CCR-08-1930. Epub 2009 Mar 24.
4
Histone deacetylase inhibitors: a new class of potential therapeutic agents for cancer treatment.组蛋白去乙酰化酶抑制剂：一类新型的癌症治疗潜在治疗药物。
Clin Cancer Res. 2002 Mar;8(3):662-4.
5
In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates.拓扑异构酶II与组蛋白脱乙酰酶抑制剂之间的体内协同作用：预测相关性。
Mol Cancer Ther. 2005 Dec;4(12):1993-2000. doi: 10.1158/1535-7163.MCT-05-0194.
6
Response to epirubicin in patients with superficial bladder cancer and expression of the topoisomerase II alpha and beta genes.表浅性膀胱癌患者对表柔比星的反应以及拓扑异构酶IIα和β基因的表达
Int J Cancer. 1996 Jan 3;65(1):63-6. doi: 10.1002/(SICI)1097-0215(19960103)65:1<63::AID-IJC11>3.0.CO;2-J.
7
Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial.组蛋白去乙酰化酶抑制剂丙戊酸对拓扑异构酶I抑制剂卡瑞替尼在黑色素瘤中的增效作用：转化研究及I/II期临床试验
Clin Cancer Res. 2009 Apr 1;15(7):2479-87. doi: 10.1158/1078-0432.CCR-08-1931. Epub 2009 Mar 24.
8
Valproic acid treatment of glioblastoma multiforme in a child.丙戊酸治疗儿童多形性胶质母细胞瘤
Pediatr Blood Cancer. 2004 Aug;43(2):181. doi: 10.1002/pbc.20083.
9
Clinical studies of histone deacetylase inhibitors.组蛋白去乙酰化酶抑制剂的临床研究。
Clin Cancer Res. 2009 Jun 15;15(12):3958-69. doi: 10.1158/1078-0432.CCR-08-2785. Epub 2009 Jun 9.
10
Histone deacetylase inhibitors.
Clin Adv Hematol Oncol. 2004 Nov;2(11):722-3.

引用本文的文献

1
Characteristic analysis of adverse reactions of histone deacetylase inhibitors based on WHO-VigiAccess.基于世界卫生组织药物不良反应数据库（WHO-VigiAccess）的组蛋白去乙酰化酶抑制剂不良反应特征分析
Front Pharmacol. 2025 Mar 18;16:1563797. doi: 10.3389/fphar.2025.1563797. eCollection 2025.
2
Histone Deacetylase Inhibitor Sensitizes ERCC1-High Non-small-Cell Lung Cancer Cells to Cisplatin via Regulating miR-149.组蛋白去乙酰化酶抑制剂通过调控miR-149使ERCC1高表达的非小细胞肺癌细胞对顺铂敏感。
Mol Ther Oncolytics. 2020 May 8;17:448-459. doi: 10.1016/j.omto.2020.05.001. eCollection 2020 Jun 26.
3
A novel histone deacetylase inhibitor, CKD5, has potent anti-cancer effects in glioblastoma.
一种新型组蛋白脱乙酰酶抑制剂CKD5在胶质母细胞瘤中具有强大的抗癌作用。
Oncotarget. 2017 Feb 7;8(6):9123-9133. doi: 10.18632/oncotarget.13265.
4
BIM upregulation and ROS-dependent necroptosis mediate the antitumor effects of the HDACi Givinostat and Sorafenib in Hodgkin lymphoma cell line xenografts.BIM 上调和 ROS 依赖性坏死性凋亡介导 HDACi 吉维司他和索拉非尼在霍奇金淋巴瘤细胞系异种移植物中的抗肿瘤作用。
Leukemia. 2014 Sep;28(9):1861-71. doi: 10.1038/leu.2014.81. Epub 2014 Feb 24.
5
Epigenetic alterations in osteosarcoma: promising targets.骨肉瘤中的表观遗传改变：有前景的靶点。
Mol Biol Rep. 2014 May;41(5):3303-15. doi: 10.1007/s11033-014-3193-7. Epub 2014 Feb 6.
6
Efficacious proteasome/HDAC inhibitor combination therapy for primary effusion lymphoma.有效蛋白酶体/HDAC 抑制剂联合治疗原发性渗出性淋巴瘤。
J Clin Invest. 2013 Jun;123(6):2616-28. doi: 10.1172/JCI64503. Epub 2013 May 1.
7
Combinatorial treatment of DNA and chromatin-modifying drugs cause cell death in human and canine osteosarcoma cell lines.联合应用 DNA 和染色质修饰药物可导致人及犬骨肉瘤细胞系发生细胞死亡。
PLoS One. 2012;7(9):e43720. doi: 10.1371/journal.pone.0043720. Epub 2012 Sep 5.
8
Newly emerging therapies targeting viral-related lymphomas.针对病毒相关性淋巴瘤的新兴治疗方法。
Curr Oncol Rep. 2011 Oct;13(5):416-26. doi: 10.1007/s11912-011-0186-8.
9
Melanoma: a model for testing new agents in combination therapies.黑色素瘤：联合治疗中测试新药物的模型。
J Transl Med. 2010 Apr 20;8:38. doi: 10.1186/1479-5876-8-38.
10
The histone deacetylase inhibitor valproic acid sensitizes human and canine osteosarcoma to doxorubicin.组蛋白去乙酰化酶抑制剂丙戊酸使人类和犬骨肉瘤对阿霉素敏感。
Cancer Chemother Pharmacol. 2011 Jan;67(1):83-92. doi: 10.1007/s00280-010-1287-z. Epub 2010 Mar 20.